Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series

TARRYTOWN, N.Y.,May 9, 2012/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will participate in the J. P. Morgan Biotech: CEO/CFO Conference Call Series at10:00 a.m. Eastern TimeonFriday, May 11, 2012.

Conference call details are as follows:Live conference call (US):  (888) 889-1309Live conference call (Outside the US):  (773) 756-0161Passcode:  BIOTECH

Replay (US):  (888) 568-0720Replay (Outside the US):  (402) 998-1481Passcode:  1017

A recording of the call will be available for telephone replay untilMay 17, 2012.

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products inthe United States, ARCALYST®(rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site atwww.regeneron.com.